Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Gilead Sciences, Leerink
Gilead upgraded to outperform by Leerink on PrEP outlook
Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for the prevention of HIV infection. Read more here.
Gilead Sciences, Inc. (GILD) Stock Rated Outperform by Leerink Partners
On Tuesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $88.16 which represents a slight increase of $1.87 or 2.17% from the prior close of $86.29. The stock opened at $85.
Why Gilead Sciences (GILD) Dipped More Than Broader Market Today
Gilead Sciences (GILD) closed the latest trading day at $87.23, indicating a -1.05% change from the previous session's end. This move lagged the S&P 500's daily loss of 0.92%. Meanwhile, the Dow experienced a drop of 0.
Gilead upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $96, up from $74. The stock has appreciated following
Leerink Partners Upgrades Gilead Sciences (GILD)
Fintel reports that on October 21, 2024, Leerink Partners upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Market Perform to Outperform. Analyst Price Forecast Suggests 3.16% Downside As of September 24,
16h
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Signaturefd LLC
Signaturefd LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 12.1% in the third ...
Yahoo Finance
1d
Gilead and MSD to advance once-weekly HIV treatment to Phase III
Gilead
Sciences and MSD are advancing their once-weekly HIV treatment regimen to Phase II trials, following promising ...
FierceBiotech
2d
Merck-Gilead long-acting oral combo suppresses HIV for 48 weeks, setting stage for pivotal program
Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...
1d
Balanced Outlook on Gilead Sciences Amid Anticipated Anito-cel Trial Results
Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Gilead Sciences (GILD – Research Report) and keeping the price ...
2d
on MSN
Calls of the Day: Gilead, Berkshire Hathaway and SLB
Donald Trump showed up for his quick shift at McDonald's in Feasterville ready to take orders at the drive-thru.
5d
Gilead withdraws bladder cancer drug in US after failed trial
Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...
1d
Morgan Stanley says anito-cel Phase 2 data next catalyst for Gilead, Arcellx
Morgan Stanley notes that Gilead (GILD) and Arcellx’s (ACLX) anito-cel, a BCMA-directed CAR-T therapy in development for relapsed / ...
FiercePharma
5d
Gilead pulls Trodelvy's approval in bladder cancer after trial flop, FDA discussions
Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...
BioSpace
5d
Gilead Withdraws ADC Trodelvy in Bladder Cancer After Trial Failure
The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...
1d
Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024
Gilead Sciences, Inc. (Nasdaq: GILD) today announced new research to be presented at The Liver Meeting® 2024, hosted by the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
NASDAQ
United States
HIV
Trodelvy
Food and Drug Administration
Feedback